Metformin: A hopeful promise in aging research

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 3, 2016, Pages

  Novelle, Marta G ^a,b,c   Ali, Ahmed ^a   Diéguez, Carlos ^c   Bernier, Michel ^a   de Cabo, Rafael ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

AGING; ARTICLE; DRUG MECHANISM; HUMAN; INVERTEBRATE MODEL; MEDICAL RESEARCH; NONHUMAN; RODENT MODEL; TRANSLATIONAL RESEARCH; DRUG EFFECTS; LIFE EXPECTANCY; PHYSIOLOGY;

AGING; HUMANS; LIFE EXPECTANCY; METFORMIN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84959566618     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025932     Document Type: Article

References (110)

1. Adeyemo MA, McDuffie JR, Kozlosky M, Krakoff J, Calis KA, Brady SM, Yanovski JA. 2014 Effects of metformin on energy intake and satiety in obese children. Diabetes Obes Metab 17: 363–370
2. Aldea M, Craciun L, Tomuleasa C, Berindan-Neagoe I, Kacso G, Florian IS, Crivii C. 2014 Repositioning metformin in cancer: Genetics, drug targets, and new ways of delivery. Tumour Biol 35: 5101–5110
3. American Diabetes Association. 2014 Standards of medical care in diabetes—2014. Diabetes Care 37: S14–S80
4. Anisimov VN. 2014 Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med 2: 60
5. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, et al. 2005a. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40: 685–693
6. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV. 2005b. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139: 721–723
7. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, et al. 2008.Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7: 2769–2773
8. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. 2010a. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9: 188–197
9. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, et al. 2010b. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging 2: 945–958
10. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. 2011 If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging 3: 148–157
11. Anisimov VN, Zabezhinski MA, Popovich IG, Pliss GB, Bespalov VG, Alexandrov VA, Stukov AN, Anikin IV, Alimova IN, Egormin Pcapital A C, et al. 2012 Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging. Expert Opin Drug Discov 7: 85–95
12. Anisimov VN, Popovich IG, Zabezhinski MA, Egormin PA, Yurova MN, Semenchenko AV, Tyndyk ML, Panchenko AV, Trashkov AP, Vasiliev AG, et al. 2015 Sex differences in aging, life span and spontaneous tumorigenesis in 129/ Sv mice neonatally exposed to metformin. Cell Cycle 14: 46–55
13. Bailey CJ, Turner RC. 1996 Metformin. N Engl J Med 334: 574–579
14. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, Leverve XM. 2006 The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38: 33–42
15. Baur JA, Birnbaum MJ. 2014 Control of gluconeogenesis by metformin: Does redox trump energy charge? Cell Metab 20: 197–199
16. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand- Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F. 2011.Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71: 4366–4372
17. Berstein LM. 2012.Metformin in obesity, cancer and aging: Addressing controversies. Aging 4: 320–329
18. Blagosklonny MV. 2013 Big mice die young but large animals live longer. Aging 5: 227–233
19. Blagosklonny MV, Campisi J. 2008 Cancer and aging:More puzzles, more promises? Cell Cycle 7: 2615–2618
20. Bulterijs S. 2011 Metformin as a geroprotector. Rejuvenation Res 14: 469–482
21. Cabreiro F, Gems D. 2013 Worms need microbes too: Microbiota, health and aging in Caenorhabditis elegans. EMBO Mol Med 5: 1300–1310
22. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. 2013.Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153: 228–239
23. Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, Radovick S, Wondisford FE, He L. 2014 Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem 289: 20435–20446
24. Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell’Orto P, et al. 2013 The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109: 2792–2797
25. Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao J, Ding L, Zhang J, Wen A. 2013 Pharmacogenetic variation and metformin response. Curr Drug Metab 14: 1070–1082
26. Cho YM, Kieffer TJ. 2011 New aspects of an old drug: Metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer. Diabetologia 54: 219–222
27. Choi CI, Lee YD, Gwag BJ, Cho SI, Kim SS, Suh-Kim H. 2008 Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice. J Neurol Sci 268: 40–47
28. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. 2006 Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab 291: E182–E189
29. Contreras C, Novelle MG, Leis R, Dieguez C, Skrede S, Lopez M. 2013 Effects of neonatal programming on hypothalamic mechanisms controlling energy balance. Horm Metab Res 45: 935–944.
30. de Cabo R, Carmona-Gutierrez D, Bernier M, Hall MN, Madeo F. 2014 The search for antiaging interventions: From elixirs to fasting regimens. Cell 157: 1515–1526
31. De Haes W, Frooninckx L, Van Assche R, Smolders A, Depuydt G, Billen J, Braeckman BP, Schoofs L, Temmerman L. 2014 Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci 111: E2501–E2509
32. Dhahbi JM, Mote PL, Fahy GM, Spindler SR. 2005 Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics 23: 343–350
33. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. 2010 Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 162: 193–212
34. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. 2007 Metformin inhibits mammalian target of rapamycin- dependent translation initiation in breast cancer cells. Cancer Res 67: 10804–10812
35. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. 2000 Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223–228
36. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA. 2013 Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6: 395–402
37. Fontaine E. 2014 Metformin and respiratory chain complex. I: The last piece of the puzzle? Biochem J 463: e3–e5
38. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. 2010 Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2355–2369
39. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. 2014 Metformin: From mechanisms of action to therapies. Cell Metab 20: 953–966
40. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, O’Neill HM, Ford RJ, Palanivel R, O’Brien M, et al. 2013 Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 19: 1649–1654
41. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, et al. 2001 Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50: 856–861
42. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. 2012 Metformin pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22: 820–827
43. reenhill C. 2015 Gastric cancer:Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer. Nat Rev Gastroenterol Hepatol 12: 124
44. Guarente L. 2008 Mitochondria—Anexus for aging, calorie restriction, and sirtuins? Cell 132: 171–176
45. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. 2003 Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulinreceptor substrate-2. J Clin Endocrinol Metab 88: 1323–1332
46. Hardie DG, Ross FA, Hawley SA. 2012 AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251–262
47. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. 2002 The antidiabetic drug metformin activates theAMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51: 2420–2425
48. Hirsch HA, Iliopoulos D, Struhl K. 2013.Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci 110: 972–977
49. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, et al. 2013 Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36: 1304–1311
50. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schonbeck U, Libby P. 2006.Metformin inhibits proinflammatory responses and nuclear factor-kB in human vascular wall cells. Arterioscler Thromb Vasc Biol 26: 611–617
51. Jafari M, Khodayari B, Felgner J, Bussel II, Rose MR, Mueller LD. 2007 Pioglitazone: An anti-diabetic compound with anti-aging properties. Biogerontology 8: 639–651
52. Johnson SC, Rabinovitch PS, Kaeberlein M. 2013 mTOR is a key modulator of ageing and age-related disease. Nature 493: 338–345
53. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et al. 2010 Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390–401
54. Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ. 2011 Metformin treatment has no beneficial effect in a doseresponse survival study in the SOD1G93A mouse model of ALS and is harmful in female mice. PLoS ONE 6: e24189
55. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, et al. 2008 Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57: 306–314
56. Kim MH, Jee JH, Park S, Lee MS, Kim KW, Lee MK. 2014 Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol 220: 117–128
57. Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H, et al. 2012 Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS ONE 7: e43056
58. Ko EM, Sturmer T, Hong JL, Castillo WC, Bae-Jump V, Funk MJ. 2015.Metformin and the risk of endometrial cancer: A population-based cohort study. Gynecol Oncol 136: 341–347
59. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P, et al. 2005 The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437: 1109–1111
60. Lapierre LR, Hansen M. 2012 Lessons from C. elegans: Signaling pathways for longevity. Trends Endocrinol Metab 23: 637–644
61. LaRue BL, Padilla PA. 2011 Environmental and genetic preconditioning for long-term anoxia responses requires AMPK in Caenorhabditis elegans. PLoS ONE 6: e16790
62. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. 2014 Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134: 607–614
63. Lenaerts I, Walker GA, Van Hoorebeke L, Gems D, Vanfleteren JR. 2008Dietary restriction of Caenorhabditis elegans by axenic culture reflects nutritional requirement for constituents provided by metabolically active microbes. J Gerontol A Biol Sci Med Sci 63: 242–252
64. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al. 2011.AMPKphosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376–388
65. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. 2012 Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 96: 187–195
66. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, LeRoith D, Wisnivesky JP. 2015 Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med 191: 448–454
67. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, McDougall G, Wang HH, Xue L, Jiang H, et al. 2012 Cellular responses to the metal-binding properties of metformin. Diabetes 61: 1423–1433
68. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR. 2007.Metformin therapy in a transgenic mouse model of Huntington’s disease. Neurosci Lett 411: 98–103
69. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, Mac- Donald MJ, et al. 2014.Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510: 542–546
70. Mahmood K, Naeem M, Rahimnajjad NA. 2013 Metformin: The hidden chronicles of a magic drug. Eur J Intern Med 24: 20–26
71. Maida A, Lamont BJ, Cao X, Drucker DJ. 2011 Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-a in mice. Diabetologia 54: 339–349
72. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. 2010 Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9: 1057–1064
73. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, et al. 2013 Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192
74. Menendez JA, Cufi S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. 2011 Gerosuppressant metformin: Less is more. Aging 3: 348–362
75. Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S, Wondisford FE, He L. 2014 Metformin activates AMP-activated protein kinase by promoting formation of the abg heterotrimeric complex. J Biol Chem 290: 3793–3802
76. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. 2012 Of mice and men: The benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev 11: 390–398
77. Miles JM, Rule AD, Borlaug BA. 2014 Use of metformin in diseases of aging. Curr Diab Rep 14: 490
78. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. 2013 Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494: 256–260
79. Na HJ, Park JS, Pyo JH, Lee SH, Jeon HJ, Kim YS, Yoo MA. 2013 Mechanism of metformin: Inhibition of DNA damage and proliferative activity in Drosophila midgut stem cell. Mech Ageing Dev 134: 381–390
80. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. 2014 Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 41: 61–68
81. Olsen A, Vantipalli MC, Lithgow GJ. 2006 Using Caenorhabditis elegans as a model for aging and age-related diseases. Ann NY Acad Sci 1067: 120–128
82. Onken B, Driscoll M. 2010 Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN- 1 PLoS ONE 5: e8758
83. Owen MR, Doran E, Halestrap AP. 2000 Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607–614
84. Patrone C, Eriksson O, Lindholm D. 2014 Diabetes drugs and neurological disorders: New views and therapeutic possibilities. Lancet Diabetes Endocrinol 2: 256–262
85. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. 2014.Metformin pharmacogenomics: Current status and future directions. Diabetes 63: 2590–2599
86. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, et al. 2008 Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 8: 157–168
87. Pernicova I, Korbonits M. 2014 Metformin—Mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10: 143–156
88. Pulito C, Donzelli S, Muti P, Puzzo L, Strano S, Blandino G. 2014. microRNAs and cancer metabolism reprogramming: The paradigm of metformin. Ann Transl Med 2: 58
89. Rego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. 2015 Effects of metformin on head and neck cancer: A systematic review. Oral Oncol 51: 416–422
90. Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD. 2009 Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology 150: 4794–4801
91. Scarpello JH. 2003 Improving survival with metformin:The evidence base today. DiabetesMetab 29: 6S36–6S43
92. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M. 2007 Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 6: 280–293
93. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. 2009 Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326: 140–144
94. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642–1646
95. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, et al. 2002 Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22: 2283–2293
96. Slack C, Foley A, Partridge L. 2012 Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila. PLoS ONE 7: e47699
97. Smith DL Jr, Elam CF Jr, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB. 2010 Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci 65: 468–474
98. Spindler SR. 2006 Use of microarray biomarkers to identify longevity therapeutics. Aging Cell 5: 39–50
99. Stenesen D, Suh JM, Seo J, Yu K, Lee KS, Kim JS, Min KJ, Graff JM. 2013 Adenosine nucleotide biosynthesis and AMPK regulate adult life span and mediate the longevity benefit of caloric restriction in flies. Cell Metab 17: 101–112
100. Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, Viollet B, Guigas B. 2011 Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 54: 3101–3110
101. Stevanovic D, Janjetovic K, Misirkic M, Vucicevic L, Sumarac- Dumanovic M, Micic D, Starcevic V, Trajkovic V. 2012 Intracerebroventricular administration of metformin inhibits ghrelin-induced hypothalamic AMP-kinase signalling and food intake. Neuroendocrinology 96: 24–31
102. Tohyama D, Yamaguchi A. 2010 A critical role of SNF1A/ dAMPKa (Drosophila AMP-activated protein kinasea) in muscle on longevity and stress resistance in Drosophila melanogaster. Biochem Biophys Res Commun 394: 112–118
103. Wang CP, Lorenzo C, Espinoza SE. 2014 Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J Endocrinol Diabetes Obes 2: 1030
104. Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, Guo X, Guo T, Botchlett R, Qi T, et al. 2014 Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS ONE 9: e91111
105. Yin M, Zhou J, Gorak EJ, Quddus F. 2013 Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist 18: 1248–1255
106. Yuan L, Ziegler R, Hamann A. 2003 Metformin modulates insulin post-receptor signaling transduction in chronically insulin-treated Hep G2 cells. Acta Pharmacol Sin 24: 55–60
107. Zarse K, Schmeisser S, Groth M, Priebe S, Beuster G, Kuhlow D, Guthke R, Platzer M, Kahn CR, Ristow M. 2012 Impaired insulin/IGF1 signaling extends life span by promoting mitochondrial L-proline catabolism to induce a transient ROS signal. Cell Metab 15: 451– 465
108. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, Li B, Liu G, Cai D. 2013 Hypothalamic programming of systemic ageing involving IKK-b, NF-kB and GnRH.Nature 497: 211–216
109. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. 2001 Role of AMPactivated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174
110. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WGt, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. 2004 Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279: 43940–43951.